A Predictive Tool to Estimate the Risk of Axillary Metastases in Breast Cancer Patients with Negative Axillary Ultrasound
|
|
- Marcus Evans
- 6 years ago
- Views:
Transcription
1 Ann Surg Oncol (2014) 21: DOI /s ORIGINAL ARTICLE BREAST ONCOLOGY A Predictive Tool to Estimate the Risk of Axillary Metastases in Breast Cancer Patients with Negative Axillary Ultrasound T. J. Meretoja, MD, PhD 1, P. S. Heikkilä, MD, PhD 2, A. S. Mansfield, MD 1, G. Cserni, MD, DSc, PhD 3,4, E. Ambrozay, MD 5, G. Boross, MD 6, J. Zgajnar, MD, PhD 7, A. Perhavec, MD, PhD 7, B. Gazic, MD 8, R. Arisio, MD, PhD 9, T. F. Tvedskov, MD, PhD 10, M.-B. Jensen, MSc 11, and M. H. K. Leidenius, MD, PhD 1 1 Breast Surgery Unit, Helsinki University Central Hospital, Helsinki, Finland; 2 Department of Pathology, Helsinki University Central Hospital, Helsinki, Finland; 3 Department of Pathology, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary; 4 Department of Pathology, University of Szeged, Szeged, Hungary; 5 Department of Radiology, Mamma ZRT, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary; 6 Department of Surgery, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary; 7 Department of Surgical Oncology, Institute of Oncology, Ljubljana, Slovenia; 8 Department of Pathology, Institute of Oncology, Ljubljana, Slovenia; 9 Department of Pathology, A.O. Citta della salute e della scienza-sant Anna Hospital, Turin, Italy; 10 Department of Breast Surgery, Copenhagen University Hospital, Copenhagen, Denmark; 11 Danish Breast Cancer Cooperative Group, Copenhagen University Hospital, Copenhagen, Denmark ABSTRACT Background. Sentinel node biopsy (SNB) is the gold standard in axillary staging in clinically node-negative breast cancer patients. However, axillary treatment is undergoing a paradigm shift and studies are being conducted on whether SNB may be omitted in low-risk patients. The purpose of this study was to evaluate the risk factors for axillary metastases in breast cancer patients with negative preoperative axillary ultrasound. Methods. A total of 1,395 consecutive patients with invasive breast cancer and SNB formed the original patient series. A univariate analysis was conducted to assess risk factors for axillary metastases. Binary logistic regression analysis was conducted to form a predictive model based on the risk factors. The predictive model was first validated internally in a patient series of 566 further patients and then externally in a patient series of 2,463 patients from four other centers. All statistical tests were two-sided. Electronic supplementary material The online version of this article (doi: /s ) contains supplementary material, which is available to authorized users. Ó Society of Surgical Oncology 2014 First Received: 6 January 2014; Published Online: 25 March 2014 T. J. Meretoja, MD, PhD tuomo.meretoja@fimnet.fi Results. A total of 426 of the 1,395 (30.5 %) patients in the original patient series had axillary lymph node metastases. Histological size (P \ 0.001), multifocality (P \ 0.001), lymphovascular invasion (P \ 0.001), and palpability of the primary tumor (P \ 0.001) were included in the predictive model. Internal validation of the model produced an area under the receiver operating characteristics curve (AUC) of and external validation an AUC of Conclusions. We present a predictive model to assess the patient-specific probability of axillary lymph node metastases in patients with clinically node-negative breast cancer. The model performs well in internal and external validation. The model needs to be validated in each center before application to clinical use. Axillary lymph node dissection (ANLD) was the gold standard in the diagnosis and treatment of axillary lymph node metastases in breast cancer for decades. Because of a significant risk of morbidity, a few randomized trials were conducted, to evaluate whether omission of ALND is safe in low-risk breast cancer patients. 1 3 The results of these studies reported acceptable axillary recurrence rates and similar survival in patients with ALND or without any axillary surgery. 1 3 The encouraging results from these studies have been published after the introduction of sentinel node biopsy (SNB) and have perhaps not gained best possible attention
2 2230 T. J. Meretoja et al. in the breast cancer research community. However, SNB also is an invasive procedure associated not only with costs but also with a certain risk of long-time morbidity, although less so than ALND. 4 6 Moreover, preoperative axillary ultrasound is a routine procedure in many breast surgery units nowadays. Approximately 50 % of patients with axillary involvement can be identified preoperatively. 7 For these reasons, a new randomized trial has been launched in Milan to evaluate whether SNB can be safely omitted in patients with negative preoperative axillary ultrasound. 8 The results of this trial are still to come. In any case, omission of axillary surgery in breast cancer patients poses the problem of unknown lymph node status and thus may complicate the planning of adjuvant chemoand/or radiotherapy. For the aforementioned reasons, the purpose of this study was to identify risk factors for axillary metastases in breast cancer patients with negative axillary ultrasound and to construct a predictive model to evaluate the risk of axillary metastases in these patients. We further aim to validate our model internally with patients from our own unit and externally using patient series from other institutions. Such predictive model could prove valuable in weighing pros and cons of SNB in individual patients. METHODS Original Patient Series The original series of this study comprises of a consecutive series of 1,395 patients having SNB for primary, invasive breast cancer at the Breast Surgery Unit of Helsinki University Central Hospital (HUCH) from July 2010 to May 2012 (Table 1). Preoperative axillary ultrasound was performed in all patients and a fine-needle aspiration biopsy was acquired whenever suspicious nodes were encountered by ultrasound. General, while subjective, criteria for suspicious nodes in ultrasound included enlargement, structural abnormality, and cortical thickening. Negative axillary ultrasound thus includes patients with no suspicious nodes or with suspicious nodes but tumor-negative in fine-needle aspiration biopsy. Patients having had neoadjuvant treatment or having recurrent breast cancer were excluded from this study. Information on patients, procedures, tumors, and axillary status were collected from a prospectively gathered sentinel node database of the HUCH. The patients were grouped as axillary node-negative or -positive. Patients with isolated tumor cells (ITC) as their only axillary finding (pn0i?) were included in the node-negative group. Patient and tumor characteristics for these two groups are given in Table 1. Surgical techniques as well as pathological workup of the breast and axillary specimen were conducted according to normal clinical routine as described in detail earlier. 9 Shortly, all patients underwent either wide local excision or mastectomy. Patients with sentinel node metastases larger than 2 mm underwent routine ALND. Patients with sentinel node metastases not larger than 2 mm or those with ITC either underwent or avoided ALND according to risk of residual disease in the axilla, evaluated using our own previously published nomogram. 10 Altogether, 439 patients underwent SNB and completion ALND, whereas 936 underwent SNB only. Twenty patients with unsuccessful SNB underwent direct ALND of level I II axillary lymph nodes. Specialized breast pathologists examined the breast specimen. We also approached molecular subtypes of the tumors according to an immunohistochemistry-based surrogate classification. 11,12 Internal Validation Series A total of 566 further consecutive patients, with similar inclusion criteria to the original patient series, formed the internal validation series. These patients were operated between May 2012 and December 2012 at HUCH. Surgical treatment and pathology methodology were similar to the original patient series. External Validation Series Four European centers participated in this study and delivered patient information on a total of 2,463 patients to form the external validation series. The inclusion criteria were similar to the original patient series. The surgical treatment and pathology methodology were conducted according to each center s daily practice. The participating centers in the external validation were: Sant Anna Hospital, Turin, Italy (1,863 patients operated between 2003 and 2012), Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary (200 patients operated between 2010 and 2012), Copenhagen University Hospital, Denmark (200 patients operated in 2011), Institute of Oncology, Ljubljana, Slovenia (200 patients operated in 2012). Statistical Analyses A univariate analysis was conducted to assess risk factors for axillary metastases. Distribution of continuous variables was analyzed using the Mann Whitney U test, and the v 2 test was used for categorical variables. All statistical tests were two-sided with P values \ 0.05 considered significant.
3 Risk of Axillary Metastases in Breast Cancer 2231 TABLE 1 Univariate analysis comparing patients with axillary lymph node metastases to those with no metastases in the original patient series Axillary lymph node metastases (n = 426) No axillary lymph node metastases (n = 969) All patients (n = 1,395) P Histological size of the primary tumor (mm) Median (range) 19 (4 80) 13 (1 150) 15 (1 150) Standard deviation Histological tumor size by T-class pt1 (2 20 mm) 253 (24.5 %) 778 (75.5 %) 1,031 pt1a (1 5 mm) 3 (4.8 %) 60 (95.2 %) 63 pt1b (6 10 mm) 39 (12.0 %) 287 (88.0 %) 326 pt1c (11 20 mm) 211 (32.9 %) 431 (67.1 %) 642 pt2 (21 50 mm) 163 (47.0 %) 184 (53.0 %) 347 pt3 (51 mm or larger) 10 (58.8 %) 7 (41.2 %) 17 Body mass index 0.74 Median (range) 25.5 (16 56) 25.5 (12 55) 25.5 (12 56) Standard deviation Patient age (year) \50 98 (44.3 %) 123 (55.7 %) 221 C (27.9 %) 846 (72.1 %) 1,174 Multifocality of the primary tumor No 310 (27.5 %) 816 (72.5 %) 1,126 Yes 116 (43.1 %) 153 (56.9 %) 269 Lymphovascular invasion in the primary tumor No 287 (24.8 %) 870 (75.2 %) 1,157 Yes 137 (61.7 %) 85 (38.3 %) 222 Missing Estrogen receptor status 0.24 Negative 38 (26.2 %) 107 (73.8 %) 145 Positive 385 (31.0 %) 857 (69.0 %) 1,242 Missing Progesterone receptor status 0.18 Negative 118 (28.0 %) 303 (72.0 %) 421 Positive 305 (31.6 %) 660 (68.4 %) 965 Missing HER-2 status 0.22 Negative 370 (30.1 %) 861 (69.9 %) 1,231 Positive 56 (34.8 %) 105 (65.2 %) 161 Missing Histological grade of the primary tumor Grade I 95 (22.5 %) 327 (77.5 %) 422 Grade II 187 (32.0 %) 398 (68.0 %) 585 Grade III 143 (37.6 %) 237 (62.4 %) 380 Missing Histology of the primary tumor 0.04 Ductal carcinoma 300 (30.8 %) 673 (69.2 %) 973 Lobular carcinoma 75 (35.2 %) 138 (64.8 %) 213 Other 50 (24.0 %) 158 (76.0 %) 208 Missing Biological subtype Luminal A 168 (25.3 %) 496 (74.7 %) 664 Luminal B 183 (39.0 %) 286 (61.0 %) 469
4 2232 T. J. Meretoja et al. TABLE 1 continued Axillary lymph node metastases (n = 426) No axillary lymph node metastases (n = 969) All patients (n = 1,395) P Luminal HER-2 34 (31.8 %) 73 (68.2 %) 107 HER-2 enriched 21 (39.6 %) 32 (60.4 %) 53 Triple negative 15 (18.5 %) 75 (81.5 %) 92 Missing Palpability of the primary tumor Not palpable 77 (16.9 %) 378 (83.1 %) 455 Palpable 343 (37.6 %) 570 (62.4 %) 913 Missing Localization of the primary tumor Central 70 (40.7 %) 102 (59.3 %) 172 Upper medial 55 (22 %) 195 (78 %) 250 Lower medial 26 (25.5 %) 76 (74.5 %) 102 Upper lateral 202 (31.6 %) 437 (68.4 %) 639 Lower lateral 73 (32.4 %) 152 (67.6 %) 225 Missing Reporting two-sided P values HER-2 human epidermal growth factor receptor 2 Variables with P values \0.1 in the univariate analysis were included in a binary logistic regression analysis using a backward stepwise likelihood ratio method. The logistic regression analysis was used as a basis for a predictive model, which included all variables with P values \0.05. The predictive model was validated both internally and externally by independent patient series. Area under the receiver operating characteristic curve (AUC) was used to evaluate the discrimination of the model and Hosmer Lemeshow goodness-of-fit test was used to assess the calibration of the model. Calibration was further characterized by plotting quintiles of predicted probability against actual probability of axillary metastases. Sensitivity and specificity of the model were calculated for various cutoff values. SPSS Statistics version 20 (SPSS Inc., Chicago, IL) software was used to conduct the statistical analyses. Ethical Considerations All patient information in this study was gathered anonymously and retrospectively with no influence on patient therapy. Institutional review boards and ethical committees were consulted in each center as required. RESULTS Of the 1,395 (30.5 %) patients in the original patient series, 426 had axillary lymph node metastases; 100 patients had micrometastasis as their largest lymph node metastasis and 326 patients had macrometastases. Of the 969 node-negative patients, 105 had ITC in their axillary lymph nodes. Factors associating with axillary metastases in the univariate analysis were patient age (P \ 0.001), histological size of the primary tumor (P \ 0.001), multifocality (P \ 0.001), lymphovascular invasion (P \ 0.001), histological grade (P \ 0.001), molecular subtype (P \ 0.001), histology of the tumor (P = 0.04), palpable tumor (P \ 0.001), and tumor localization (P = 0.001; Table 1). Histological size (P \ 0.001), multifocality (P \ 0.001), lymphovascular invasion (P \ 0.001), and palpability of the primary tumor (P \ 0.001) remained statistically significant in the multivariate logistic regression analysis and were included in the predictive model (Table 2). The model produced a P value of 0.41 for the Hosmer Lemeshow goodness-of-fit test indicating a good fit and calibration of the model. The AUC for the original patient series was (95 % confidence interval [CI] ), which suggests a good discrimination. A mathematical model was generated from the logistic regression analysis to predict the risk of axillary metastases, with p denoting the probability of axillary metastases: logitðpþ ¼ 2:260 þ 0:564 a þ 1:404 b þ 0:595 c þ 0:036 d: The letters in the equation denote the variables: a = multifocality of the primary tumor (1 if multifocal, 0 if unifocal); b = lymphovascular invasion in the primary
5 Risk of Axillary Metastases in Breast Cancer 2233 TABLE 2 Binary logistic regression analysis using backward stepwise likelihood ratio method in the original patient series Coefficient Wald P Odds ratio 95 % CI for odds ratio Lower Upper Multifocality of the primary tumor Lymphovascular invasion in the primary tumor Palpability of the primary tumor Histological size of the primary tumor Constant CI confidence interval Reporting two-sided P values TABLE 3 Performance of the predictive model in internal and external validation N Preoperative axillary ultrasound performed Patients with axillary metastases AUC (95 % CI) Sensitivity Specificity Patients with predicted risk \30 % Original patient series 1, (30.5 %) With all information available 1, (30.9 %) ( ) (60.6 %) Internal validation series (26 %) ( ) (67.1 %) External validation series 2, (36.3 %) 0.79 ( ) (47.7 %) Center A (Turin) 1, (38.9 %) ( ) (43.9 %) Center B (Kecskemét) (24.5 %) ( ) (54 %) Center C (Copenhagen) (29.5 %) ( ) (69 %) Center D (Ljubljana) (31.5 %) ( ) (56 %) AUC area under the receiver operating characteristics curve, CI confidence interval Sensitivity and specificity calculated for a cutoff value of \30 % risk estimate score tumor (1 if present, 0 if not); c = palpability of the primary tumor (1 if palpable, 0 if not); d = histological size of the primary tumor in mm. The predictive model is given as a supplementary Excel-file calculator (Supplementary data 1) and at the website of the breast surgery unit of HUCH predictivemodel. The model was validated by entering patient data from the internal and external validation series into the equation. 147 of the 566 (26.0 %) patients in the internal validation series and 895 of the In the external validation series, 2,463 (36.3 %) patients had axillary metastases. AUC were calculated for each patient series (Table 3). Calibration of the model for the original and the external validation series is plotted in Fig. 1. Sensitivity and specificity for each patient series are given for a cutoff value of less than 30 % risk estimate in Table 3. Sensitivity and specificity of the model for other cutoff values in the external validation center with the largest number of patients (N = 1863) are given in Table 4. Only one patient in the original series, none in the internal validation series, and three patients in the external validation series had a risk estimate of less than 10 % for axillary metastases. Actual Probability of Axillary Lymph Node Metastases 80% 70% 60% 50% 40% 30% 20% 10% 0% 0% 10% 20% 30% 40% 50% 60% 70% 80% Predicted Probability of Axillary Lymph Node Metastases DISCUSSION Reference Line Original Patient Series External Validation Series FIG. 1 Calibration of the model in the original patient series and the external validation series Present Predictive Model The current study presents a predictive model for probability of axillary lymph node metastases in patients
6 2234 T. J. Meretoja et al. TABLE 4 Sensitivity and specificity of our model for various cutoff values for the largest external validation center Center A (Turin) N = 1,863 Sensitivity with breast cancer who are clinically node-negative with axillary ultrasound. The model performs well in internal validation and external validation in four European centers, in terms of AUC. Furthermore, the model is well calibrated in terms of Hosmer Lemeshow goodness-of-fit test. The proportion of patients with less than 10 % risk of axillary metastases was negligible in all patient series of this study. This finding is in agreement with a study evaluating risk factors for sentinel node metastases in a large patient series. 13 The proportion of node-positive patients in the ALND arm was 23 and 28 % in the two previous reports comparing ALND and observation, and it was approximately 30 % in most of the series entered into this study. 2,3 Therefore, we have reported the sensitivity and specificity of our model for a 30 % cutoff value in Table 3. However, our model provides a continuous patient-specific risk estimate and therefore is not tied to specific cutoff thresholds. This is an advantage of the model, because the clinical decision-making thresholds may well change in the future. Risk Factors in our Model Specificity Number of patients in the low-risk group \20 % risk (32.9 %) \30 % risk (43.9 %) \40 % risk (52.3 %) \50 % risk ,215 (65.2 %) Histological tumor size, multifocality, lymphovascular invasion, and palpability of the primary tumor were included in the predictive model, because they were found to be risk factors for axillary metastases in logistic regression analysis. All of these have been reported as risk factors for axillary metastases in previous studies We gave no instructions to the external validation centers for how to define or record the different variables in order to retain the external patient series as close to daily practice as possible. Multifocality of the primary tumor is defined in our original series and internal validation series as any tumor with histologically two or more separate foci irrespective of the distance between them. Similar definition of multifocality is used in the external validation centers B and D. External validation center A defines multifocality as two foci separated by 5 mm or more and center C as more than 20 mm of nonneoplastic parenchyma. Nonetheless, the model performed best in the external validation center A with a different definition of multifocality but the largest number of patients. Additionally, palpability of the primary tumor is a crude subjective measure, which may differ substantially according to examiner. Furthermore, core-needle biopsy may produce a palpable hematoma, which may incorrectly be interpreted as a palpable tumor. Therefore, the assessment of tumor palpability before core-needle biopsy is essential, and the tumors were generally defined as not palpable if there was any doubt of the finding. Preoperative Axillary Ultrasound Preoperative axillary ultrasound was performed in all patients of the original series and the internal validation series. Axillary ultrasound with needle biopsy of any suspicious nodes reveals preoperatively a substantial proportion of patients with axillary metastases and therefore decreases the probability of finding axillary metastases in axillary surgery. 7 Centers that do not perform preoperative axillary ultrasound thus have a larger proportion of clinically node-negative patients with axillary metastases found in SNB. Preoperative axillary ultrasound was performed at all of the external validation centers but not on all patients. However, the proportion of patients having had preoperative axillary ultrasound did not seem to affect the performance of the model. Surprisingly, the external validation center with the lowest proportion of preoperative axillary ultrasounds had the best performance of the model in terms of AUC (Center A in Table 3). Comparison to Previous Models To our knowledge, the study by Bevilacqua et al. from Memorial Sloan-Kettering Cancer Center (MSKCC) reports the most widely used prediction tool that provides a continuous risk estimate. 14 The patients in the MSKCC model have been operated in the beginning of sentinel node era between 1996 and Internal validation of the MSKCC model produced a similar AUC of to our present model. A few other models use a nomogram or table of categories to estimate a risk of axillary metastases. 13,15 The MSKCC model included the same risk factors of tumor size, multifocality, and lymphovascular invasion as our model. In addition, the MSKCC model included patient age, tumor location, and estrogen and progesterone receptor status. The MSKCC modeling group of patients included tumor palpability, but the information was not gathered in the validation series and palpability was not included in the predictive model.
7 Risk of Axillary Metastases in Breast Cancer 2235 Implications of Our Model Our predictive model may have numerous clinical implications. The triple diagnosis, that is clinical examination, breast imaging, and image-guided needle biopsy may fail in some patients, especially in those with small tumors and therefore a low risk of axillary metastasis. 16 In these patients, breast cancer diagnosis is achieved by surgical biopsy and possible SNB would be performed as a second operation after the final histological analyses of the surgical biopsy specimen. Therefore, all the variables of our predictive model would be available before axillary surgery. Thus, the value of axillary surgery in these patients could be contemplated on the basis of an individual risk prediction, in a multidisciplinary breast cancer meeting, as well as with the patient herself. Both the recently launched Milan trial and the two aforementioned previous studies had or will have certain inclusion criteria, such as age older than 60 or 65 years, clinically T1N0 tumor, or breast conservation and radiotherapy. 2,3,8 The results of these studies cannot be directly applied to patients not fulfilling the inclusion criteria. Our model may offer a useful tool to estimate the possibility of omitting SNB, although the trial criteria were not met. Similarly, a patient with breast cancer might meet trial criteria preoperatively, but final histology may reveal risk factors that could warrant second stage axillary surgery. Finally, our model could even be used as a surrogate to surgical axillary staging. Staging the axilla by mathematically predicting the risk of axillary lymph node metastases may not be as accurate as SNB but may, nonetheless, be used in the planning of adjuvant chemo- and/or radiotherapy in patients without axillary surgery and hence an unknown lymph node status. Limitations of Our Model The value of our model in the preoperative decisionmaking is limited, because many risk factors, such as tumor size and multifocality as well as lymphovascular invasion, cannot be accurately assessed before surgery. Moreover, undetected axillary disease may have different influence on breast cancer recurrence and survival according to various patient and tumor related factors, such as age, tumor grade, or hormone-receptor status. In addition, systemic adjuvant treatment and radiotherapy both influence the clinical significance of undetected axillary disease. Our model is only able to predict the presence of axillary metastases but not their clinical significance, that is, whether they will remain occult or develop into clinical axillary recurrence or lead to systemic disease. CONCLUSIONS We present a predictive model to assess the patientspecific probability of axillary lymph node metastases in patients with clinically node-negative breast cancer. The model performs well in internal and external validation. The model needs to be validated in each center before application to clinical use. ACKNOWLEDGMENT Funding The first author of this study was supported by grants from the Academy of Finland, Orion-Farmos Research Foundation, Emil Aaltonen s Foundation, and Maud Kuistila Memorial Foundation. The funders did not have any involvement in the design of the study, the collection, analysis, and interpretation of the data, the writing of the article, or the decision to submit the article for publication. DISCLOSURE REFERENCES The authors have declared no conflicts of interest. 1. Veronesi U, Orecchia R, Zurrida S, et al. Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy. Ann Oncol. 2005;16(3): Rudenstam CM, Zahrieh D, Forbes JF, et al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial J Clin Oncol. 2006;24(3): Martelli G, Boracchi P, Ardoino I, Lozza L, Bohm S, Vetrella G, Agresti S. Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer: 15-year results of a randomized controlled trial. Ann Surg. 2012;256(6): Ashikaga T, Krag DN, Land SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102(2): McLaughlin SA, Wright MJ, Morris KT, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviors. J Clin Oncol. 2008;26(32): Gärtner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA. 2009;302(18): Diepstraten S, Sever A, Buckens C, et al. Value of preoperative ultrasound-guided axillary lymph node biopsy for preventing completion axillary lymph node dissection in breast cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2014; 21(1): Gentilini O, Veronesi U. Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND). Breast. 2012;21(5): Meretoja TJ, Leidenius MH, Heikkila PS, Joensuu H. Sentinel node biopsy in breast cancer patients with large or multifocal tumors. Ann Surg Oncol. 2009;16(5): Meretoja TJ, Strien L, Heikkilä PS, Leidenius MH. A simple nomogram to evaluate the risk of nonsentinel node metastases in breast cancer patients with minimal sentinel node involvement. Ann Surg Oncol. 2012;19(2):
8 2236 T. J. Meretoja et al. 11. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19): Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10): Viale G, Zurrida S, Maiorano E, et al. Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution. Cancer. 2005; 103(3): Bevilacqua JL, Kattan MW, Fey JV, Cody HS, Borgen PI, Van Zee KJ. Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. J Clin Oncol. 2007;25(24): Reyal F, Rouzier R, Depont-Hazelzet B, et al. The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma. PLoS One. 2011;6(5):e Leidenius MH, Vironen JH, von Smitten KA, Heikkilä PS, Joensuu H. The outcome of sentinel node biopsy in breast cancer patients with preoperative surgical biopsy. J Surg Oncol. 2009; 99(7):420 3.
Debate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest
Debate Axillary dissection - con Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Summer School of Oncology, third edition Updated Oncology 2015: State of the Art News & Challenging Topics Bucharest,
More informationEvaluation of the Axilla Post Z-0011 Trial New Paradigm
Evaluation of the Axilla Post Z-0011 Trial New Paradigm Belinda Curpen, MD, FRCPC; Tetyana Dushenkovska; Mia Skarpathiotakis MD, FRCPC; Carrie Betel, MD, FRCPC; Kalesha Hack, MD, FRCPC; Lara Richmond,
More informationThe Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer
The Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer Le défi des traitements locorégionaux individualisés pour les patientes présentant un cancer du sein
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationSurgical Therapy: Sentinel Node Biopsy and Breast Conservation
Surgical Therapy: Sentinel Node Biopsy and Breast Conservation Stephen B. Edge, MD Professor of Surgery and Oncology Roswell Park Cancer Institute University at Buffalo Dr. Roswell Park: Tradition in Cancer
More informationPosition Statement on Management of the Axilla in Patients with Invasive Breast Cancer
- Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
:$;7)#*8'-87*4BCD'E7)F'31$4.$&'G$H'E7)F&'GE'>??ID >?,"'@4,$)4*,#74*8'!74/)$++'74',"$'A.,.)$'7%'()$*+,'!*42$)!7)74*67&'!3 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationThe Role of Sentinel Lymph Node Biopsy and Axillary Dissection
The Role of Sentinel Lymph Node Biopsy and Axillary Dissection Henry Mark Kuerer, MD, PhD, FACS Department of Surgical Oncology University of Texas MD Anderson Cancer Center SLN Biopsy Revolutionized surgical
More informationWhy Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA Why Do Axillary Dissection? 6 August 2011 Implications
More informationSentinel Node Biopsy. Is There Any Role for Axillary Dissection? JCCNB Nov 20, Stephen B. Edge, MD
Sentinel Node Biopsy Is There Any Role for Axillary Dissection? JCCNB Nov 20, 2010 Tokyo, Japan Stephen B. Edge, MD Roswell Park Cancer Institute University at Buffalo Buffalo, NY USA SNB with Clinically
More informationSentinel Lymph Node Biopsy for Breast Cancer
Sentinel Lymph Node Biopsy for Breast Cancer Registrar Tutorial Adam Cichowitz Surgical Registrar The Royal Melbourne Hospital Sentinel Lymph Node Biopsy Axillary LN status important prognostic factor
More informationApplicability of the ACOSOG Z0011 Criteria in Women with High-Risk Node-Positive Breast Cancer Undergoing Breast Conserving Surgery
Ann Surg Oncol (2015) 22:1128 1132 DOI 10.1245/s10434-014-4090-y ORIGINAL ARTICLE BREAST ONCOLOGY Applicability of the ACOSOG Z0011 Criteria in Women with High-Risk Node-Positive Breast Cancer Undergoing
More informationAt many centers in the United States and worldwide,
ORIGINAL ARTICLES A Declining Rate of Completion Axillary Dissection in Sentinel Lymph Node-positive Breast Cancer Patients Is Associated With the Use of a Multivariate Nomogram Julia Park, MS, Jane V.
More informationUltrasound or FNA for Predicting Node Positive in Breast Cancer
Ultrasound or FNA for Predicting Node Positive in Breast Cancer Chiun Sheng Huang, MD, PhD, MPH Professor and Chairman Department of Surgery Director of Breast Care Center National Taiwan University Hospital
More informationPrediction of Lymph Node Involvement in Patients with Breast Tumors Measuring 3 5 cm in a Middle-Income Setting: the Role of CancerMath
DOI 10.1007/s00268-014-2752-3 BRIEF ORIGINAL SCIENTIFIC REPORT Prediction of Lymph Node Involvement in Patients with Breast Tumors Measuring 3 5 cm in a Middle-Income Setting: the Role of CancerMath E.
More informationRadiotherapy Implications of ACOSOG Z-11 for Clinical Practice. Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin
1 Radiotherapy Implications of ACOSOG Z-11 for Clinical Practice Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin Disclosures: none Agenda 1. ACOSOG Z-11: Another perspective
More informationShould a Sentinel Node Biopsy Be Performed in Patients with High-Risk Breast Cancer?
Should a Sentinel Node Biopsy Be Performed in Patients with High-Risk Breast Cancer? The Harvard community has made this article openly available. Please share how this access benefits you. Your story
More informationANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:
1 ANNEX 1 OBJECTIVES At the completion of the training period, the fellow should be able to: 1. Breast Surgery Evaluate and manage common benign and malignant breast conditions. Assess the indications
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationHow to Use MRI Following Neoadjuvant Chemotherapy (NAC) in Locally Advanced Breast Cancer
Global Breast Cancer Conference 2016 & 5 th International Breast Cancer Symposium April 29 th 2016, 09:40-10:50 How to Use MRI Following Neoadjuvant Chemotherapy (NAC) in Locally Advanced Breast Cancer
More informationRNA preparation from extracted paraffin cores:
Supplementary methods, Nielsen et al., A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer.
More informationThe Beginning radical Radical Mastectomy mastectomy
Controversies about Surgical Treatment of Breast Cancer Schlomo Schneebaum MD Breast Health Center Department of Surgery Tel-Aviv Sourasky Medical, Center Tel-Aviv ISRAEL 2nd International Congress of
More information16/09/2015. ACOSOG Z011 changing practice. Presentation outline. Nodal mets #1 prognostic tool. Less surgery no change in oncologic outcomes
ACOSOG Z011 changing practice The end of axillary US/FNA? Preoperative staging of the axilla in the era of Z011 Adena S Scheer MD MSc FRCSC Surgical Oncologist, St. Michael s Hospital Assistant Professor,
More informationFeasibility Of Day Surgery In Patients With Breast
583201SJS0010.1177/1457496915583201K. Ojala, J. H. Vironen, K. Mattila, A. M. Eklund, M. H. K. Leidenius, T. J. MeretojaScandinavian Journal of Surgery research-article2015 ORIGINAL ARTICLE Scandinavian
More informationDuctal Carcinoma in Situ (DCIS)
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Ductal Carcinoma in Situ (DCIS) Ductal Carcinoma in Situ DCIS Versions 2002 2017: Audretsch / Blohmer / Brunnert / Budach /
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More informationM D..,., M. M P.. P H., H, F. F A.. A C..S..
Implications of NSABP B-32 and Loco-Regional Therapy Considerations After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H, F.A.C.S. Professor of Surgery Northeastern Ohio Medical University Medical
More informationBreast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015
Breast Surgery When Less is More and More is Less E MacIntosh, MD June 6, 2015 Presenter Disclosure Faculty: E. MacIntosh Relationships with commercial interests: None Mitigating Potential Bias Not applicable
More informationDiagnosis and staging of breast cancer and multidisciplinary team working
1 Diagnosis and staging of breast cancer and multidisciplinary team working Common symptoms and signs Over 90% of breast cancers (BCs) are local or regional when first detected. At least 60% of patients
More informationClinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy
Case Series Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy Ling Xu 1*, Fang Li 1,2*, Yinhua Liu 1, Xuening Duan 1, Jingming Ye 1,
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationFeasibility of using negative ultrasonography results of axillary lymph nodes to predict sentinel lymph node metastasis in breast cancer patients
Received: 21 April 2018 Revised: 14 May 2018 DOI: 10.1002/cam4.1606 Accepted: 14 May 2018 ORIGINAL RESEARCH Feasibility of using negative ultrasonography results of axillary lymph nodes to predict sentinel
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationRelevance. Axillary Node Recurrence. Purpose. Case Presentation: Is axillary staging required? Two trends have emerged:
Axillary Node Recurrence N.L. Davis Associate Professor of Surgery, UBC Head of Surgical Oncology, BCCA Relevance In an attempt to minimize long term complications and to maximize cancer control, the management
More informationRecent Update in Surgery for the Management of Breast Cancer
Recent Update in Surgery for the Management of Breast Cancer Wonshik Han, MD, PhD Professor, Department of Surgery, Seoul National University College of Medicine Chief of Breast Care Center, Seoul National
More informationBreast Imaging: Multidisciplinary Approach. Madelene Lewis, MD Assistant Professor Associate Program Director Medical University of South Carolina
Breast Imaging: Multidisciplinary Approach Madelene Lewis, MD Assistant Professor Associate Program Director Medical University of South Carolina No Disclosures Objectives Discuss a multidisciplinary breast
More informationShould Breast Density Influence Patient Selection for Breast-Conserving Surgery?
Ann Surg Oncol (2013) 20:600 606 DOI 10.1245/s10434-012-2604-z ORIGINAL ARTICLE BREAST ONCOLOGY Should Breast Density Influence Patient Selection for Breast-Conserving Surgery? Nimmi S. Kapoor, MD 1, Anne
More informationFinancial Disclosure. Learning Objectives. None. To understand the clinical applicability of the NCDB Breast Cancer PUF
Preoperative Prediction of Node Negative Disease After Neoadjuvant Chemotherapy in Patients Presenting with Node Negative or Node Positive Breast Cancer Brittany L Murphy MD, Tanya Hoskin MS, Courtney
More informationWhat is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine
What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine What is Cancer? Layman s terms: cancer starts when cells grow out of control (in any place in the body) and crowd out normal cells
More informationIs Complete Axillary Dissection Needed Following Mastectomy and Sentinel Node Biopsy for N1 disease?
Is Complete Axillary Dissection Needed Following Mastectomy and Sentinel Node Biopsy for N1 disease? Mylin A. Torres, MD Director, Glenn Family Breast Center Louis and Rand Glenn Family Chair in Breast
More informationEVALUATION OF AXILLARY LYMPH NODES AFTER NEOADJUVANT SYSTEMIC THERAPY KIM, MIN JUNG SEVERANCE HOSPITAL, YONSEI UNIVERSITY
EVALUATION OF AXILLARY LYMPH NODES AFTER NEOADJUVANT SYSTEMIC THERAPY KIM, MIN JUNG SEVERANCE HOSPITAL, YONSEI UNIVERSITY AXILLARY LYMPH NODE METASTASIS Axillary lymph node metastasis is one of the most
More informationTargeting Surgery for Known Axillary Disease. Abigail Caudle, MD Henry Kuerer, MD PhD Dept. Surgical Oncology MD Anderson Cancer Center
Targeting Surgery for Known Axillary Disease Abigail Caudle, MD Henry Kuerer, MD PhD Dept. Surgical Oncology MD Anderson Cancer Center Nodal Ultrasound at Diagnosis Whole breast and draining lymphatic
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationDoctoral dissertation Tove Filtenborg Tvedskov. The evolution of the sentinel node procedure in the treatment of breast cancer
Doctoral dissertation Tove Filtenborg Tvedskov The evolution of the sentinel node procedure in the treatment of breast cancer From Section of Breast Surgery Department of Plastic Surgery, Breast Surgery
More informationEDITORIAL. Ann Surg Oncol (2011) 18: DOI /s
Ann Surg Oncol (2011) 18:2407 2412 DOI 10.1245/s10434-011-1593-7 EDITORIAL Multidisciplinary Considerations in the Implementation of the Findings from the American College of Surgeons Oncology Group (ACOSOG)
More informationOccult Axillary Node Metastases in Breast Cancer Are Prognostically Significant: Results in 368 Node-Negative Patients With 20-Year Follow-Up
VOLUME 26 NUMBER 11 APRIL 10 2008 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Occult Axillary Node Metastases in Breast Cancer Are Prognostically Significant: Results in 368 Node-Negative
More informationEvaluation of Pathologic Response in Breast Cancer Treated with Primary Systemic Therapy
Evaluation of Pathologic Response in Breast Cancer Treated with Primary Systemic Therapy Eun Yoon Cho, MD, PhD Department of Pathology and Translational Genomics Samsung Medical Center Sungkyunkwan University
More informationORIGINAL ARTICLE BREAST ONCOLOGY
Ann Surg Oncol DOI 10.1245/s10434-017-5932-1 ORIGINAL ARTICLE BREAST ONCOLOGY Predicting Nodal Positivity in Women 70 Years of Age and Older with Hormone Receptor-Positive Breast Cancer to Aid Incorporation
More informationAdvances in Breast Surgery. Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015
Advances in Breast Surgery Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015 Objectives Understand the surgical treatment of breast cancer Be able to determine when a lumpectomy
More informationAudit. Public Health Monitoring Report on 2006 Data. National Breast & Ovarian Cancer Centre and Royal Australasian College of Surgeons.
National Breast & Ovarian Cancer Centre and Royal Australasian College of Surgeons Audit Public Health Monitoring Report on 2006 Data November 2009 Prepared by: Australian Safety & Efficacy Register of
More information/pjs
POLSKI PRZEGLĄD CHIRURGICZNY 05, 87, 6, 9094 0.55/pjs-05-0056 Problems concerning patients qualification for surgical procedures allowing for evaluation of the condition of axillary fossa lymph nodes in
More informationNeoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
More informationNomogram for prediction of level 2 axillary lymph node metastasis in proven level 1 node-positive breast cancer patients
/, 2017, Vol. 8, (No. 42), pp: 72389-72399 Nomogram for prediction of level 2 axillary lymph node metastasis in proven level 1 node-positive breast cancer patients Yanlin Jiang 1,*, Hong Xu 2,*, Hao Zhang
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationWhat the surgeon wants from the radiologist before breast cancer surgery. Erica Patocskai Isabelle Trop
What the surgeon wants from the radiologist before breast cancer surgery Erica Patocskai Isabelle Trop Centre Hospitalier de l université de Montréal CAR, April 2013 Plan What is the role of MRI for breast
More informationRepeating Conservative Surgery after Ipsilateral Breast Tumor Reappearance: Criteria for Selecting the Best Candidates
Ann Surg Oncol (2012) 19:3771 3776 DOI 10.1245/s10434-012-2404-5 ORIGINAL ARTICLE BREAST ONCOLOGY Repeating Conservative Surgery after Ipsilateral Breast Tumor Reappearance: Criteria for Selecting the
More informationCURRENT CONTROVERSIES IN BREAST CANCER SURGERY Less or more!?
CURRENT CONTROVERSIES IN BREAST CANCER SURGERY Less or more!? I have no Disclosures Wolfgang Gatzemeier Breast Unit Milan, Italy 17th ESO-ESMO- EONS Masterclass in Clinical Oncology 24-29 MARCH 2018 Optimal
More informationPMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
More informationPost Neoadjuvant therapy: issues in interpretation
Post Neoadjuvant therapy: issues in interpretation Disclosure: Overview D Prognostic features in assessment of post treatment specimens: Tumor size Cellularity Grade Receptors LN Neoadjuvant chemotherapy:
More informationUse of the dye guided sentinel lymph node biopsy method alone for breast cancer metastasis to avoid unnecessary axillary lymph node dissection
456 Use of the dye guided sentinel lymph node biopsy method alone for breast cancer metastasis to avoid unnecessary axillary lymph node dissection TOMOKO TAKAMARU 1, GORO KUTOMI 1, FUKINO SATOMI 1, HIROAKI
More informationPrinciples of breast radiation therapy
ANZ 1601/BIG 16-02 EXPERT ESMO Preceptorship Program 2017 Principles of breast radiation therapy Boon H Chua Professor Director of Cancer and Haematology Services UNSW Sydney and Prince of Wales Hospital
More informationEvaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients
BIOSCIENCES BIOTECHNOLOGY RESEARCH ASIA, December 2015. Vol. 12(3), 2221-2225 Evaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients S.M. Hosseini¹, H. Shahbaziyan
More informationPrediction of Postoperative Tumor Size in Breast Cancer Patients by Clinical Assessment, Mammography and Ultrasonography
Prediction of Postoperative Tumor Size in Breast Cancer Patients by Clinical Assessment, Mammography and Ultrasonography Eyad Fawzi AlSaeed 1 and Mutahir A. Tunio 2* 1 Consultant Radiation Oncology, Chairman
More informationDuctal Carcinoma-in-Situ: New Concepts and Controversies
Ductal Carcinoma-in-Situ: New Concepts and Controversies James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationCase Scenario 1 History and Physical 3/15/13 Imaging Pathology
Case Scenario 1 History and Physical 3/15/13 The patient is an 84 year old white female who presented with an abnormal mammogram. The patient has a five year history of refractory anemia with ringed sideroblasts
More informationControversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE
Controversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE Neoadjuvant Chemotherapy Indications: Management of locally advanced invasive breast cancers including inflammatory breast
More informationSTAGE CATEGORY DEFINITIONS
CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX Tis Tis (DCIS) Tis (LCIS) Tis (Paget s) T1 T1mi T1a T1b T1c a b c
More informationAudit Report. Breast Cancer Quality Performance Indicators. Patients diagnosed during Published: December 2015 NORTH OF SCOTLAND PLANNING GROUP
NORTH OF SCOTLAND PLANNING GROUP Breast Cancer Managed Clinical Network Audit Report Breast Cancer Quality Performance Indicators Patients diagnosed during Published: December 2015 Mr Douglas Brown NOSCAN
More informationSurgical Issues in Neoadjuvant Chemotherapy
14 th Bossche Mamma Congress Ruwenbergstraat 7 5271 AG Sint Michielsgestel June 14, 2016 Surgical Issues in Neoadjuvant Chemotherapy Tari A. King MD FACS Chief, Breast Surgery Dana Farber/Brigham and Women
More informationIs There a Need for Axillary Dissection in Breast Cancer?
225 Is There a Need for Axillary Dissection in Breast Cancer? Jason P. Wilson, MD a ; David Mattson, MD b ; and Stephen B. Edge, MD a ; Buffalo, New York Key Words Axillary node dissection, breast cancer,
More informationClinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy
Clinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy Mitsui Memorial Hospital Department of Breast and Endocine surgery Daisuke Ota No financial support
More informationSENTINEL LYMPH NODE BIOPSY FOR PATIENTS WITH EARLY-STAGE BREAST CANCER
SENTINEL LYMPH NODE BIOPSY FOR PATIENTS WITH EARLY-STAGE BREAST CANCER Clinical Practice Guideline Update Introduction The original ASCO evidence-based clinical practice guidelines on use of sentinel node
More informationTHE SURGEON S ROLE: THE AXILLA. Owen A Ung University of Queensland Royal Brisbane and Women s Hospital Wesley and St Andrews Hospital
THE SURGEON S ROLE: THE AXILLA Owen A Ung University of Queensland Royal Brisbane and Women s Hospital Wesley and St Andrews Hospital What are the concerns with treatment to the axilla Not necessary for
More informationUnexpected features of breast cancer subtype
Liu et al. World Journal of Surgical Oncology (2015) 13:249 DOI 10.1186/s12957-015-0665-8 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Unexpected features of breast cancer subtype Ye-huan Liu,
More informationDonna Plecha, MD 1, Shiyu Bai, BS 2, Helen Patterson 3, Cheryl Thompson, PhD 4, and Robert Shenk, MD 5
Ann Surg Oncol DOI 10.1245/s10434-015-4527-y ORIGINAL ARTICLE BREAST ONCOLOGY Improving the Accuracy of Axillary Lymph Node Surgery in Breast Cancer with Ultrasound-Guided Wire Localization of Biopsy Proven
More informationPrognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes
Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes G. Cancello, P. Maisonneuve, N. Rotmensz, G. Viale, M. G. Mastropasqua, G.
More informationLoco-Regional Management After Neoadjuvant Chemotherapy
1 Loco-Regional Management After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationRadiation Field Design and Regional Control in Sentinel Lymph Node-Positive Breast Cancer Patients With Omission of Axillary Dissection
Original Article Radiation Field Design and Regional Control in Sentinel Lymph Node-Positive Breast Cancer Patients With Omission of Axillary Dissection Jeremy Setton, MD 1 ; Hiram Cody, MD 2 ; Lee Tan,
More informationPage 1. AD vs. no AD. Survival. Randomized Trials. All trials reported higher survival in the AD group. Years. Node-NegativeNegative
Sentinel Node Biopsy: The Past, The Present, and The Future Thomas B. Julian, M.D., F.A.C.S. Associate Professor of Human Oncology Drexel University College of Medicine Director of Breast Surgical Oncology
More informationTable of contents. Page 2 of 40
Page 1 of 40 Table of contents Introduction... 4 1. Background Information... 6 1a: Referral source for the New Zealand episodes... 6 1b. Invasive and DCIS episodes by referral source... 7 1d. Age of the
More informationEvolution of Regional Nodal Management of Breast Cancer
Evolution of Regional Nodal Management of Breast Cancer Bruce G. Haffty, MD Director (Interim) Rutgers Cancer Institute of New Jersey Professor and Chair Department of Radiation Oncology Rutgers, The State
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More information03/14/2019. Postmastectomy radiotherapy; the meta-analyses, and the paradigm change to altered fractionation Mark Trombetta M.D.
radiotherapy; the meta-analyses, and the paradigm change to altered fractionation Mark Trombetta M.D. Division of Radiation Oncology Allegheny Health Network Cancer Institute Professor of Radiation Oncology
More informationAssessment of Ultrasound Features Predicting Axillary Nodal Metastasis in Breast Cancer: The Impact of Cortical Thickness
THIEME E19 Assessment of Ultrasound Features Predicting Axillary Nodal Metastasis in Breast Cancer: The Impact of Cortical Thickness Authors A. Stachs 1, A. Tra-Ha Thi 1, M. Dieterich 1, J. Stubert 1,
More informationDepartment of General Surgery, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore
International Scholarly Research Network ISRN Oncology Volume 20, Article ID 539503, 7 pages doi:0.5402/20/539503 Research Article Predictors of Nonsentinel Nodal Involvement to Aid Intraoperative Decision
More information2017 San Antonio Breast Cancer Symposium: Local Therapy Highlights
2017 San Antonio Breast Cancer Symposium: Local Therapy Highlights Mylin A. Torres, M.D. Director, Glenn Family Breast Center Associate Professor Department of Radiation Oncology Winship Cancer Institute
More informationLoco-Regional Management After Neoadjuvant Chemotherapy
1 Loco-Regional Management After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationRADIOTHERAPY IN BREAST CANCER :
RADIOTHERAPY IN BREAST CANCER : PAST, PRESENT, FUTURE Dr Jyotirup Goswami Consultant Radiation Oncologist Narayana Cancer Institute Narayana Superspecialty Hospital Breast cancer is the classic paradigm
More informationCryoablation in the Management of Early Stage Breast Cancer
13 th Annual Pacific Northwest Breast and Gynecologic Care Conference Cryoablation in the Management of Early Stage Breast Cancer Dennis R. Holmes, M.D., Inc. Int. Director, Margie Peterson Breast Center
More informationDescriptor Definition Author s notes TNM descriptors Required only if applicable; select all that apply multiple foci of invasive carcinoma
S5.01 The tumour stage and stage grouping must be recorded to the extent possible, based on the AJCC Cancer Staging Manual (7 th Edition). 11 (See Tables S5.01a and S5.01b below.) Table S5.01a AJCC breast
More informationPAPER. Long-term Outcome of Patients Managed With Sentinel Lymph Node Biopsy Alone for Node-Negative Invasive Breast Cancer
ONLINE FIRST AER Long-term Outcome of atients Managed With Sentinel Lymph Node Biopsy Alone for Node-Negative Invasive Breast Cancer Nimmi S. Kapoor, MD; Myung-Shin Sim, DrH; Jennifer Lin, MD; Armando
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Appropriate Use of Healthcare 2019 COLLECTION TYPE:
More informationSCIENCE CHINA Life Sciences
SCIENCE CHINA Life Sciences RESEARCH PAPER April 2013 Vol.56 No.4: 335 340 doi: 10.1007/s11427-013-4435-y Risk factors of recurrence in small-sized, node negative breast cancer in young women: a retrospective
More informationSurgical Management of the Axilla
Surgical Management of the Axilla Jean-Francois Boileau, MD, MSc, FRCSC Surgical Oncologist, Montreal Jewish General Hospital Segal Cancer Centre Associate Member, Department of Oncology, McGill University
More informationPage 1. AHN-JHU Breast Cancer Symposium. Novel Local Regional Clinical Trials. Background. Neoadjuvant Chemotherapy Benefit.
AHN-JHU Breast Cancer Symposium Novel Local Regional Clinical Trials March 22, 2019 Thomas B. Julian, MD, FACS Associate Medical Director, Cancer Program Development, ANH Cancer Institute Background In
More informationAxillary Sentinel Node and Tumour-related Factors Associated with Non-sentinel Node Involvement in Breast Cancer
Axillary Sentinel Node and Tumour-related Factors Associated with Non-sentinel Node Involvement in Breast Cancer Gábor Cserni 1, Tomasz Burzykowski 2, Vincent Vinh-Hung 3, Lajos Kocsis 1,Gábor Boross 1,Mária
More informationManagement of the Axilla at Initial Surgery Manejo da Axila em Cirurgia Inicial
DISCIPLINA DE MASTOLOGIA ESCOLA PAULISTA DE MEDICINA UNIVERSIDADE FEDERAL DE SÃO PAULO Management of the Axilla at Initial Surgery Manejo da Axila em Cirurgia Inicial Disciplina de Mastologia Prof. Dr.
More informationResearch Article Cytokeratin on Frozen Sections of Sentinel Node May Spare Breast Cancer Patients Secondary Axillary Surgery
Pathology Research International Volume 2012, Article ID 802184, 5 pages doi:10.1155/2012/802184 Research Article Cytokeratin on Frozen Sections of Sentinel Node May Spare Breast Cancer Patients Secondary
More informationShould we still be performing IHC on all sentinel nodes?
Miami Breast Cancer Conference 31 st Annual Conference March 8, 2014 Should we still be performing IHC on all sentinel nodes? Donald L. Weaver, MD Professor of Pathology University of Vermont USA Miami
More informationImmunohistochemical classification of breast tumours
Immunohistochemical classification of breast tumours Workshop in Diagnostic Immunohistochemistry September 19 th - 21 th 2018 Anne-Vibeke Lænkholm Department of Surgical Pathology, Zealand University Hospital,
More information